The Use of Allogenic Plasma Aliquots as a Source of Plasminogen in the Treatment of Ligneous Conjunctivitis, Clinical Trial of One Case

Trial Information
Who is this study for? Patients with Ligneous Conjunctivitis
What treatments are being studied? Allogenic Plasma Aliquots, a Source of Plasminogen
Status: Enrolling by invitation
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 3
Summary

Allogenic plasma aliquots, used as eye drops, will provide a source of plasminogen in the treatment of ligneous conjunctivitis. The investigational product will be available through written request from the Sponsor-Investigator to Canadian Blood Services, as approved by Health Canada.

Am I eligible for this trial?
Participation Requirements
Sex:
Female
Healthy Volunteers:
Accepts Healthy Volunteers

• Subject diagnosed with ligneous conjunctivitis associated with Type 1 plasminogen deficiency

Where is this trial taking place?
Other Locations
Canada
Memorial University of Newfoundland
St. John's
When is this trial taking place?
Start Date: May 2023
Estimated Completion Date: May 2023
How many participants will be in this trial?
Target number of participants: 1
What treatment is being studied in this trial?
Experimental: Allogenic Plasma Aliquots
Allogenic Plasma Aliquots to be used as eye drops in the treatment of recurrences of ligneous conjunctivitis. Two drops will be administered to the affected eye, every 1 to 4 hours, depending on severity of the recurrence.
Who are the authors of this trial?
Dorothy V Bautista

This content was sourced from clinicaltrials.gov